Related Experiment Video
Updated: Jan 31, 2026
09:40
Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
Published on: May 13, 2019
11.1K
Left ventricular noncompaction with intractable heart failure responsive to empagliflozin
Yasuyuki Chiba1, Kazuya Yonezawa1, Masahumi Himeno1
1Department of Cardiology, National Hospital Organization Hakodate Hospital, Hakodate, Japan.
Journal of Cardiology Cases
|January 1, 2019
Summary
Empagliflozin effectively treated acute heart failure in a patient resistant to diuretics. This sodium-glucose cotransporter-2 inhibitor shows promise for managing heart failure from acute to chronic phases.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure management remains challenging, particularly in cases of diuretic resistance.
- The precise mechanisms of empagliflozin in acute heart failure are not fully elucidated.
- Left ventricular noncompaction is a rare cardiomyopathy associated with fluid retention.
Observation:
- A patient with left ventricular noncompaction presented with acute heart failure and fluid overload.
- The patient exhibited resistance to conventional diuretic therapies.
- Empagliflozin was administered to manage the acute heart failure symptoms.
Findings:
- Empagliflozin successfully resolved fluid retention and stabilized the patient's condition.
- No renal dysfunction or deterioration in the patient's status was observed during treatment.
- This case highlights empagliflozin's efficacy in an acute heart failure scenario.
Implications:
- Empagliflozin may be a valuable therapeutic option for acute heart failure, even in diuretic-resistant cases.
- The drug's effectiveness may extend from the acute to the chronic phases of heart failure.
- Further research into empagliflozin's mechanisms in acute heart failure is warranted.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
920
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
920
01:17Pathophysiology of Heart Failure
3.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.6K
01:27Heart Failure I: Introduction
882
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
882
01:22Heart Failure VI: Adjunct Therapies
336
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
336
01:22Heart Failure Drugs: Diuretics
966
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
966
01:30Heart Failure V: Medical Management
312
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
312